QGEN - QIAGEN N.V.

NYSE - Nasdaq Real Time Price. Currency in USD
38.64
+0.45 (+1.18%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close32.21
Open38.39
Bid38.39 x 900
Ask38.49 x 4000
Day's Range31.71 - 32.49
52 Week Range31.10 - 39.45
Volume6,152,583
Avg. Volume1,205,010
Market Cap8.714B
Beta (3Y Monthly)0.94
PE Ratio (TTM)47.41
EPS (TTM)0.81
Earnings DateMay 1, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est39.48
Trade prices are not sourced from all markets
  • Business Wire16 hours ago

    QIAGEN partners with Ares Genetics to advance global fight against antibiotic-resistant pathogens

    Frankfurt Prime Standard: QIA) today announced a broad agreement with Ares Genetics, a subsidiary of Curetis N.V. (CURE.NX), to develop innovative bioinformatics and assay solutions to accelerate research targeting the growing global health challenges posed by antibiotic-resistant bacteria. QIAGEN has acquired an exclusive license to leverage Ares Genetics’ proprietary antimicrobial resistance database, ARESdb, as well as bioinformatics tools and workflows from the ARES Technology Platform, AREStools, in QIAGEN’s bioinformatics products and services for researchers.

  • Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y
    Zacks7 days ago

    Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y

    Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.

  • The $100 Billion Investing Opportunity That Could Revolutionize Cancer Treatment
    Motley Fool9 days ago

    The $100 Billion Investing Opportunity That Could Revolutionize Cancer Treatment

    This exciting area of cancer research could turn into a huge industry. How can investors potentially profit?

  • Markit11 days ago

    See what the IHS Markit Score report has to say about Qiagen NV.

    Qiagen NV NYSE:QGENView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for QGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding QGEN totaled $10.60 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEvents11 days ago

    Edited Transcript of QGEN earnings conference call or presentation 5-Feb-19 2:00pm GMT

    Q4 2018 Qiagen NV Earnings Call

  • QIAGEN Continues to Transform
    Motley Fool12 days ago

    QIAGEN Continues to Transform

    With new products, growth at the diagnostic test company is set to accelerate this year.

  • What Kind Of Shareholders Own QIAGEN N.V. (NYSE:QGEN)?
    Simply Wall St.12 days ago

    What Kind Of Shareholders Own QIAGEN N.V. (NYSE:QGEN)?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The big shareholder groups in QIAGEN N.V.Read More...

  • Qiagen N.V. (QGEN) Q4 2018 Earnings Conference Call Transcript
    Motley Fool13 days ago

    Qiagen N.V. (QGEN) Q4 2018 Earnings Conference Call Transcript

    QGEN earnings call for the period ending December 31, 2018.

  • QIAGEN's (QGEN) Q4 Earnings In Line, Revenues Miss Mark
    Zacks14 days ago

    QIAGEN's (QGEN) Q4 Earnings In Line, Revenues Miss Mark

    QIAGEN's (QGEN) suffers sluggish sales at Americas. However, the company delivers strong global growth.

  • Qiagen (QGEN) Q4 Earnings Meet Estimates
    Zacks15 days ago

    Qiagen (QGEN) Q4 Earnings Meet Estimates

    Qiagen (QGEN) delivered earnings and revenue surprises of 0.00% and -1.43%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press15 days ago

    Qiagen: 4Q Earnings Snapshot

    The Venlo, Netherlands-based company said it had profit of 26 cents per share. Earnings, adjusted for amortization costs and non-recurring costs, came to 40 cents per share. The results met Wall Street ...

  • Business Wire15 days ago

    QIAGEN Reports Results for Fourth Quarter and Full-Year 2018

    QIAGEN reports results for fourth quarter and full-year 2018

  • Business Wire15 days ago

    QIAGEN Informatics Solutions Chosen to Support Genomics England’s Bold Five Million Genomes in Five Years Project

    Frankfurt Prime Standard:QIA) today announced that Genomics England have selected QIAGEN’s QCI (QIAGEN Clinical Insights) portfolio offering on behalf of the NHS in England to support the UK’s program to sequence, analysis and interpret 5 million genomes over the next 5 years.

  • Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
    Zacks22 days ago

    Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for

    Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wirelast month

    QIAGEN N.V. to Report Fourth Quarter and Full Year 2018 Results

    QIAGEN N.V. plans as previously announced to release its report on results for the fourth quarter 2018 on Monday, February 4 at approximately 22:05 Central European Time / 16:05 Eastern Standard Time .

  • QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands
    Zackslast month

    QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands

    QIAGEN (QGEN) progresses with plans to widen customer base for QuantiFERON-TB Gold Plus test.

  • Business Wirelast month

    QIAGEN’s QuantiFERON®-TB Gold Plus Gains Approval in Canada

    Fourth generation latent TB blood test provides flexible workflow and novel CD8 technology for a more complete picture of patients' immune response to tuberculosis infection

  • MoCo economic development officials plan satellite office in Boston
    American City Business Journalslast month

    MoCo economic development officials plan satellite office in Boston

    Hey Boston, Montgomery County wants your biotech talent. In an unprecedented move, the Montgomery County Economic Development Corp. is in the early stages of planning an office in the Boston-Cambridge area to recruit companies from the region's rich biotech and life sciences industry. Bob Buchanan, a local developer who chairs the Montgomery County Economic Development Corp., told me Wednesday afternoon the corporation will hire real estate company JLL (NYSE: JLL) to conduct a life sciences market analysis, identify recruitment opportunities and propose potential locations for the office.

  • What Does QIAGEN N.V.’s (NYSE:QGEN) P/E Ratio Tell You?
    Simply Wall St.last month

    What Does QIAGEN N.V.’s (NYSE:QGEN) P/E Ratio Tell You?

    This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). To keep it practical, we'll show how QIAGEN N.V.'s (NYSE:QGEN) P/E Read More...

  • QIAGEN Scores on Strategic Alliances, Suffers Low HPV Sales
    Zackslast month

    QIAGEN Scores on Strategic Alliances, Suffers Low HPV Sales

    QIAGEN (QGEN) pins high hopes on its strategic tie-ups with Hamilton and DiaSorin. It unveils a CE-marked DiaSorin automation solution in Europe to use the LIAISON system for test read-out.

  • Business Wirelast month

    QIAGEN to Develop QuantiFERON®-TB Access as a New Test for Low-Resource, High-Burden Regions in Global Fight Against TB

    Adapting the power of QuantiFERON®-TB technology to advance global TB control efforts in new partnership with Ellume

  • Business Wirelast month

    QIAGEN Acquires N-of-One, Expanding Its Clinical Bioinformatics Capabilities in Molecular Oncology Decision Support

    Enhancing QIAGEN’s industry-leading position with access to MarkerMine™ database and real-world evidence insights that provide insights for targeted therapy options